Hong Kong Pharma CEO, CFO, COO Resign
Ticker: HKPD · Form: 6-K · Filed: Oct 7, 2025 · CIK: 2007702
Sentiment: neutral
Topics: executive-resignation, management-change, sec-filing
TL;DR
CEO, CFO, and COO out at Hong Kong Pharma. Big changes coming?
AI Summary
Hong Kong Pharma Digital Technology Holdings Limited announced on October 6, 2025, the resignation of its Chief Executive Officer, Chief Financial Officer, and Chief Operating Officer. The company filed a Form 6-K report with the SEC on October 7, 2025, indicating these executive changes.
Why It Matters
Significant executive departures can signal internal instability or strategic shifts, potentially impacting investor confidence and the company's future direction.
Risk Assessment
Risk Level: medium — The resignation of multiple key executives simultaneously creates uncertainty about the company's leadership and operational stability.
Key Players & Entities
- Hong Kong Pharma Digital Technology Holdings Limited (company) — The company filing the report and experiencing executive changes.
- October 6, 2025 (date) — Date of the executive resignations.
- October 7, 2025 (date) — Date the Form 6-K was filed.
FAQ
Who has resigned from Hong Kong Pharma Digital Technology Holdings Limited?
The Chief Executive Officer, Chief Financial Officer, and Chief Operating Officer have resigned.
When were the resignations effective?
The resignations were effective on October 6, 2025.
What form was filed with the SEC regarding these changes?
A Form 6-K report was filed with the SEC.
What is the company's principal executive office address?
The address is Room B1, 5/F., Well Town Industrial Building, 13 Ko Fai Road, Yau Tong, Kowloon, Hong Kong.
Does the company file annual reports under Form 20-F or 40-F?
The company indicates it files annual reports under Form 20-F.
Filing Stats: 868 words · 3 min read · ~3 pages · Grade level 10.5 · Accepted 2025-10-06 18:47:09
Filing Documents
- ea0260472-6k_hongkong.htm (6-K) — 18KB
- ea026047201ex99-1_hongkong.htm (EX-99.1) — 62KB
- ea026047201ex99-2_hongkong.htm (EX-99.2) — 62KB
- ea026047201ex99-3_hongkong.htm (EX-99.3) — 59KB
- 0001213900-25-096731.txt ( ) — 201KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: October 6, 2025 Hong Kong Pharma Digital Technology Holdings Limited /s/ Liang Chenyu Name: Liang Chenyu Title: Director and Chief Executive Officer 3